MyFinsight
Home
Blog
About
Cash
$8,383,393
(13.68%↑ Y/Y)
Prepaid expenses and
other current assets
$2,259,120
(227.04%↑ Y/Y)
Due from related
party
$638
Intangible assets
$114,300,000
Goodwill
$25,744,143
Total current assets
$10,643,151
(29.14%↑ Y/Y)
Property and equipment,
net of depreciation
$322,809
(1207.50%↑ Y/Y)
Total assets
$151,010,103
(1726.79%↑ Y/Y)
Accumulated deficit
-$122,398,191
(-53.84%↓ Y/Y)
Total liabilities,
series a non-voting...
$151,010,103
(1726.79%↑ Y/Y)
Total stockholders'
equity (deficit)
-$27,694,917
(-550.49%↓ Y/Y)
Additional paid-in capital
$94,703,052
(10.49%↑ Y/Y)
Non-voting convertible
preferred stock
$121
Common stock - 0.0001
par value per share...
$101
(20.24%↑ Y/Y)
Series a non-voting
convertible preferred stock...
$143,384,776
Series a non-voting
convertible preferred stock...
$22,668,324
Total liabilities
$12,651,920
(497.15%↑ Y/Y)
Long-term liabilities
$7,253,203
(1209.92%↑ Y/Y)
Total current
liabilities
$5,398,717
(244.97%↑ Y/Y)
Contingent consideration
$6,465,000
Deferred tax liability
$457,677
Warrant liability
$330,526
(-40.31%↓ Y/Y)
Accounts payable and
accrued expenses
$4,682,359
(199.19%↑ Y/Y)
Notes payable -
convertible, at fair value
$652,411
Back
Back
Balance Sheet
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com